アポリポタンパク質A
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. リポ蛋白aと心血管疾患lipoprotein a and cardiovascular disease [show details]
… glycoprotein, apolipoprotein(a) (apo(a)), is covalently bound to apolipoprotein B by a disulfide bridge . The apo(a) chain contains five cysteine-rich domains known as "kringles" . The fourth kringle is …
- 2. 一次予防のための心血管疾患の発症リスクの評価：危険因子の計算ツールcardiovascular disease risk assessment for primary prevention risk calculators [show details]
…measurement of various apolipoproteins (apo) A-1 and B. There are numerous studies examining the power of each of these various lipoproteins in predicting CHD risk. There is generally a consensus that non-HDL …
- 3. リポ蛋白の分類、代謝、およびアテローム性動脈硬化症における役割lipoprotein classification metabolism and role in atherosclerosis [show details]
…formation of apo(a):apo B complexes requires an LDL particle of a certain morphology and composition. The structural integrity of LDL, and therefore Lp(a) formation, are modulated by LCAT . The apo(a) chain …
- 4. Gene test interpretation: Familial hypercholesterolemia genes (LDLR, APOB, PCSK9)gene test interpretation familial hypercholesterolemia genes ldlr apob pcsk9 [show details]
- 5. HDLコレステロール：異常値の臨床的側面hdl cholesterol clinical aspects of abnormal values [show details]
…human apolipoprotein A-1 by somatic gene transfer of apolipoprotein A-1 , by the administration of oral apo A-1 mimetic peptides , or by the administration of apolipoprotein A-1 Milano, which is a natural …
English Journal
- Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
- Stiekema LCA, Prange KHM, Hoogeveen RM, Verweij SL, Kroon J, Schnitzler JG, Dzobo KE, Cupido AJ, Tsimikas S, Stroes ESG, de Winther MPJ, Bahjat M.
- European heart journal. 2020 Apr;().
- Elevated lipoprotein(a) [Lp(a)] is strongly associated with an increased cardiovascular disease (CVD) risk. We previously reported that pro-inflammatory activation of circulating monocytes is a potential mechanism by which Lp(a) mediates CVD. Since potent Lp(a)-lowering therapies are emerging, it is
- PMID 32268367
- DNA methylation profiling identifies a high effect genetic variant for lipoprotein(a) levels.
- Jones GT, Marsman J, Bhat B, Phillips VL, Chatterjee A, Rodger EJ, Williams MJA, van Rij AM, McCormick SPA.
- Epigenetics. 2020 Apr;()1-10.
- Changes in whole blood DNA methylation levels at several CpG sites have been associated with circulating blood lipids, specifically high-density lipoprotein and triglycerides. This study performs a discovery and validation epigenome-wide association study (EWAS) for circulating lipoprotein(a) [Lp(a)
- PMID 32237968
- Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles Using Intrinsic Fluorescence.
- Raut S, Garud A, Nagarajan B, Sabnis N, Remaley A, Fudala R, Gryczynski I, Gryczynski Z, Dzyuba SV, Borejdo J, Lacko A.
- The Journal of pharmacology and experimental therapeutics. 2020 Apr;373(1)113-121.
- Reconstituted high-density lipoprotein (HDL) containing apolipoprotein A-I (Apo A-I) mimics the structure and function of endogenous (human plasma) HDL due to its function and potential therapeutic utility in atherosclerosis, cancer, neurodegenerative diseases, and inflammatory diseases. Recently, a
- PMID 31941718
Japanese Journal
- Evaluation of apocynin in vitro on high glucose-induced oxidative stress on tenocytes
- Kurosawa T.,Mifune Y.,Inui A.,Nishimoto H.,Ueda Y.,Kataoka T.,Yamaura K.,Mukohara S.,Kuroda R.
- Bone & Joint Research 9(1), 23-28, 2020-01
- … regular glucose with apocynin (RG apo+); … high glucose with apocynin (HG apo+); … and high glucose without apocynin (HG apo-). … Results Expression of NOX1, NOX4, and IL-6 mRNA in the HG groups was significantly higher compared with that in the RG groups, and NOX1, NOX4, and IL-6 mRNA expression in the HG apo+ group was significantly lower compared with that in the HG apo- group. …
- NAID 120006811092
- Rasagiline Pharmacokinetics are affected by cytochrome P-450 1A2 genetic variants in different doses
- Bilal Rabiea,Saud Naseem,Riffat Sualeha
- 日本薬理学会年会要旨集 93(0), 2-O-039, 2020
- … The plasma concentrations were determined using High performance liquid chromatography and pharmacokinetic variables were calculated using APO Pharmacologica software. …
- NAID 130007811549
Related Links
- これでようやく、動脈硬化とapo(a)の詳しいメカニズムの解明が可能となりました。 動脈硬化とapo(a) コレステロールを多く含む餌を与え、ウサギに動脈硬化を起こさせ、Lp(a)を持つapo(a) Tgウサギの動脈硬化病変を観察しました。
- Apo A-I may be measured when someone has a personal or family history of abnormal lipid levels and/or premature CVD.It may be ordered when a healthcare practitioner is trying to determine the cause of a person's high cholesterol and/or suspects it may be due to a disorder that is causing a deficiency in apo A-I. ...
- 悪玉LDLの"悪"の指標、アポリポ蛋白B 欧米の糖尿病者の主な死因は心・脳の大血管症です。日本でも急増中！そこで今までの管理目標悪玉コレステロールLDL-Cとは別の「アポリポ蛋白B」に注目が集まっています。
★リンクテーブル★
[★]
- 英
- apolipoprotein A、apoA、apo A
- 関
- アポリポ蛋白質A、アポリポ蛋白A、アポリポタンパクA、アポA
[★]
アポリポタンパク質A、アポリポ蛋白質A、アポリポタンパクA、アポリポ蛋白A
- 関
- apo A、apoA
[★]
- 関
- apo A、apolipoprotein A
[★]
- 英
- apoA、apo A
- 関
- アポリポタンパク質A
[★]
アポリポタンパク質A-I
[★]
アポリポタンパク質A2
[★]
- 関
- apolipoprotein
[★]
[★]
- 関
- adenoviral、adenovirus